10-QPeriod: Q3 FY2021

THERMO FISHER SCIENTIFIC INC. Quarterly Report for Q3 Ended Oct 2, 2021

Filed November 4, 2021For Securities:TMO

Summary

Thermo Fisher Scientific Inc. reported strong top-line growth in the third quarter and first nine months of 2021, driven by robust demand across its end markets, particularly in pharma and biotech, and continued contributions from COVID-19 related products and services. While revenue growth was solid, operating income saw a slight decrease in the third quarter compared to the prior year, attributed to increased strategic growth investments and a less favorable sales mix, despite productivity improvements. The company is progressing towards the significant acquisition of PPD, Inc., which is expected to close by the end of 2021, and has bolstered its financial flexibility through substantial debt issuances. Operationally, the company demonstrated resilience and growth, with significant revenue increases in its Life Sciences Solutions and Laboratory Products and Services segments. The company continues to invest in its commercial capabilities, R&D, and operational infrastructure to support long-term growth. Despite ongoing investments, the company maintained a strong cash flow from operations, providing ample liquidity to fund its near-term obligations and strategic initiatives.

Key Highlights

  • 1Total revenues increased by 9% in Q3 2021 ($9.33B) and 32% in the first nine months of 2021 ($28.51B) compared to the prior year periods, driven by organic growth and acquisitions.
  • 2Operating income for Q3 2021 was $2.28 billion, a decrease of 6% from $2.43 billion in Q3 2020, primarily due to increased strategic growth investments and sales mix.
  • 3Net income for Q3 2021 was $1.90 billion, a slight decrease from $1.93 billion in Q3 2020.
  • 4Cash flow from operating activities was robust, totaling $6.86 billion for the first nine months of 2021, up from $4.95 billion in the prior year period.
  • 5The company is on track to close the significant acquisition of PPD, Inc. for $17.4 billion plus assumption of $3.5 billion in net debt, with an expected completion by the end of 2021.
  • 6Thermo Fisher Scientific issued substantial new debt in October 2021, totaling approximately $11.83 billion, to help finance the PPD acquisition and enhance liquidity.
  • 7Significant revenue growth was observed in the Life Sciences Solutions segment (+9% in Q3, +47% YTD) and Laboratory Products and Services segment (+12% in Q3, +24% YTD).

Frequently Asked Questions

Thermo Fisher Scientific entered into a definitive agreement to acquire PPD, Inc. for $17.4 billion plus $3.5 billion of net debt. Both companies have substantially complied with the FTC's Second Request for information, and the transaction is expected to be completed by the end of 2021, subject to customary closing conditions and regulatory approvals.

Total revenues showed strong growth, increasing by 9% to $9.33 billion in the third quarter of 2021 and by 32% to $28.51 billion in the first nine months of 2021 compared to the respective periods in 2020. This growth was driven by a combination of organic demand, acquisitions, and favorable currency translation effects.

The company has a strong liquidity position, with $12.03 billion in cash and cash equivalents as of October 2, 2021. Operating activities generated $6.86 billion in cash for the first nine months of 2021. Thermo Fisher also secured significant debt financing in October 2021, totaling approximately $11.83 billion, to support the PPD acquisition and maintain financial flexibility.

The operating income margin decreased from 28.5% in Q3 2020 to 24.4% in Q3 2021. This was primarily due to increased strategic growth investments in areas like commercial capabilities, R&D, and infrastructure, as well as a less favorable sales mix, partially offset by productivity improvements and higher sales.